Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.

Restricted cell surface expression of receptor tyrosine kinase ROR1 in pediatric B-lineage acute lymphoblastic leukemia suggests targetability with therapeutic monoclonal antibodies.

Dave H, Anver MR, Butcher DO, Brown P, Khan J, Wayne AS, Baskar S, Rader C.

PLoS One. 2012;7(12):e52655. doi: 10.1371/journal.pone.0052655. Epub 2012 Dec 20.

2.

Overexpression of orphan receptor tyrosine kinase Ror1 as a putative tumor-associated antigen in Iranian patients with acute lymphoblastic leukemia.

Shabani M, Asgarian-Omran H, Jeddi-Tehrani M, Vossough P, Faranoush M, Sharifian RA, Toughe GR, Kordmahin M, Khoshnoodi J, Roohi A, Tavoosi N, Mellstedt H, Rabbani H, Shokri F.

Tumour Biol. 2007;28(6):318-26. doi: 10.1159/000121405. Epub 2008 Mar 20. Erratum in: Tumour Biol. 2008;29(2):136. Omran, Hossein Asgarian [corrected to Asgarian-Omran, Hossein].

PMID:
18354269
3.

Expression profile of orphan receptor tyrosine kinase (ROR1) and Wilms' tumor gene 1 (WT1) in different subsets of B-cell acute lymphoblastic leukemia.

Shabani M, Asgarian-Omran H, Vossough P, Sharifian RA, Faranoush M, Ghragozlou S, Khoshnoodi J, Roohi A, Jeddi-Tehrani M, Mellstedt H, Rabbani H, Shokri F.

Leuk Lymphoma. 2008 Jul;49(7):1360-7. doi: 10.1080/10428190802124000.

PMID:
18604725
4.

Receptor tyrosine kinase-like orphan receptor 1: a novel target for cancer immunotherapy.

Shabani M, Naseri J, Shokri F.

Expert Opin Ther Targets. 2015 Jul;19(7):941-55. doi: 10.1517/14728222.2015.1025753. Epub 2015 Apr 2. Review.

PMID:
25835638
5.

Detection of orphan receptor tyrosine kinase (ROR-1) expression in Egyptian pediatric acute lymphoblastic leukemia.

Shaheen I, Ibrahim N.

Fetal Pediatr Pathol. 2012 Jun;31(3):113-9. doi: 10.3109/15513815.2012.656825. Epub 2012 Feb 27.

PMID:
22369092
6.

The receptor tyrosine kinase ROR1--an oncofetal antigen for targeted cancer therapy.

Hojjat-Farsangi M, Moshfegh A, Daneshmanesh AH, Khan AS, Mikaelsson E, Osterborg A, Mellstedt H.

Semin Cancer Biol. 2014 Dec;29:21-31. doi: 10.1016/j.semcancer.2014.07.005. Epub 2014 Jul 25. Review.

PMID:
25068995
7.

Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy.

Zhang S, Cui B, Lai H, Liu G, Ghia EM, Widhopf GF 2nd, Zhang Z, Wu CC, Chen L, Wu R, Schwab R, Carson DA, Kipps TJ.

Proc Natl Acad Sci U S A. 2014 Dec 2;111(48):17266-71. doi: 10.1073/pnas.1419599111. Epub 2014 Nov 19.

8.

Targeting ROR1 identifies new treatment strategies in hematological cancers.

Karvonen H, Niininen W, Murumägi A, Ungureanu D.

Biochem Soc Trans. 2017 Apr 15;45(2):457-464. doi: 10.1042/BST20160272. Review.

PMID:
28408486
9.

ROR1 is expressed on hematogones (non-neoplastic human B-lymphocyte precursors) and a minority of precursor-B acute lymphoblastic leukemia.

Broome HE, Rassenti LZ, Wang HY, Meyer LM, Kipps TJ.

Leuk Res. 2011 Oct;35(10):1390-4. doi: 10.1016/j.leukres.2011.06.021. Epub 2011 Aug 2.

10.

The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor.

Hudecek M, Schmitt TM, Baskar S, Lupo-Stanghellini MT, Nishida T, Yamamoto TN, Bleakley M, Turtle CJ, Chang WC, Greisman HA, Wood B, Maloney DG, Jensen MC, Rader C, Riddell SR.

Blood. 2010 Nov 25;116(22):4532-41. doi: 10.1182/blood-2010-05-283309. Epub 2010 Aug 11.

11.

Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies.

Yang J, Baskar S, Kwong KY, Kennedy MG, Wiestner A, Rader C.

PLoS One. 2011;6(6):e21018. doi: 10.1371/journal.pone.0021018. Epub 2011 Jun 15.

12.

Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia.

Baskar S, Kwong KY, Hofer T, Levy JM, Kennedy MG, Lee E, Staudt LM, Wilson WH, Wiestner A, Rader C.

Clin Cancer Res. 2008 Jan 15;14(2):396-404. doi: 10.1158/1078-0432.CCR-07-1823.

13.

Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignancies.

Daneshmanesh AH, Porwit A, Hojjat-Farsangi M, Jeddi-Tehrani M, Tamm KP, Grandér D, Lehmann S, Norin S, Shokri F, Rabbani H, Mellstedt H, Österborg A.

Leuk Lymphoma. 2013 Apr;54(4):843-50. doi: 10.3109/10428194.2012.731599. Epub 2012 Oct 9.

PMID:
22988987
14.

Reduction of Minimal Residual Disease in Pediatric B-lineage Acute Lymphoblastic Leukemia by an Fc-optimized CD19 Antibody.

Seidel UJ, Schlegel P, Grosse-Hovest L, Hofmann M, Aulwurm S, Pyz E, Schuster FR, Meisel R, Ebinger M, Feuchtinger T, Teltschik HM, Witte KE, Schwarze CP, Rammensee HG, Handgretinger R, Jung G, Lang P.

Mol Ther. 2016 Sep;24(9):1634-43. doi: 10.1038/mt.2016.141. Epub 2016 Jul 6.

PMID:
27380762
15.

Inhibition of the receptor tyrosine kinase ROR1 by anti-ROR1 monoclonal antibodies and siRNA induced apoptosis of melanoma cells.

Hojjat-Farsangi M, Ghaemimanesh F, Daneshmanesh AH, Bayat AA, Mahmoudian J, Jeddi-Tehrani M, Rabbani H, Mellstedt H.

PLoS One. 2013 Apr 8;8(4):e61167. doi: 10.1371/journal.pone.0061167. Print 2013.

16.

Targeting malignant B cells with an immunotoxin against ROR1.

Baskar S, Wiestner A, Wilson WH, Pastan I, Rader C.

MAbs. 2012 May-Jun;4(3):349-61. doi: 10.4161/mabs.19870. Epub 2012 Apr 26.

17.

Targeting ROR1 inhibits epithelial-mesenchymal transition and metastasis.

Cui B, Zhang S, Chen L, Yu J, Widhopf GF 2nd, Fecteau JF, Rassenti LZ, Kipps TJ.

Cancer Res. 2013 Jun 15;73(12):3649-60. doi: 10.1158/0008-5472.CAN-12-3832.

18.

Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy.

Daneshmanesh AH, Mikaelsson E, Jeddi-Tehrani M, Bayat AA, Ghods R, Ostadkarampour M, Akhondi M, Lagercrantz S, Larsson C, Osterborg A, Shokri F, Mellstedt H, Rabbani H.

Int J Cancer. 2008 Sep 1;123(5):1190-5. doi: 10.1002/ijc.23587.

19.

High CD45 surface expression determines relapse risk in children with precursor B-cell and T-cell acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol.

Cario G, Rhein P, Mitlöhner R, Zimmermann M, Bandapalli OR, Romey R, Moericke A, Ludwig WD, Ratei R, Muckenthaler MU, Kulozik AE, Schrappe M, Stanulla M, Karawajew L.

Haematologica. 2014 Jan;99(1):103-10. doi: 10.3324/haematol.2013.090225. Epub 2013 Aug 2.

20.

ROR1 can interact with TCL1 and enhance leukemogenesis in Eμ-TCL1 transgenic mice.

Widhopf GF 2nd, Cui B, Ghia EM, Chen L, Messer K, Shen Z, Briggs SP, Croce CM, Kipps TJ.

Proc Natl Acad Sci U S A. 2014 Jan 14;111(2):793-8. doi: 10.1073/pnas.1308374111. Epub 2013 Dec 30.

Supplemental Content

Support Center